glp 1 inhibitors drugs GLP-1-based therapies for diabetes, obesity and beyond Cardiovascular and mortality outcomes with

The SURMOUNT-1 DXA substudy (Look et al., 2025) showed that tirzepatide reduced lean body mass by 10.9% over 72 weeks, compared to 2.6% with placebo

Quality Check was performed according to the established pipeline used by previous epidemiological studies and international metabolomics consortia [31, 43,44,45]

The arms race between plants and insect herbivores have driven their coevolution for hundreds of millions of years

And lets be clear, programmatic deprescribing at a population level is different than intentional, individual-level deprescribing

doi: 10.1530/EJE-08-0414

Both work to increase growth hormone levels, but in slightly different ways